Tapewire

Nasdaq · USD

INCY

INCYTE CORP

Export transactions ↓
Tapewire entity
3182
SEC CIK
0000879169
Parsed reports
950

Last 12 months

Inside the activity.

0 purchase rows · 46 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202507
Dec 202509
Jan 202602
Feb 202601
Mar 202601
Apr 202601
May 202602
Jun 202601
Jul 2026015
Aug 202605
Sep 202602
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
SaleCommon Stock 2,187 $119.47 $261,280.89
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 18

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,160

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
SaleCommon Stock 5,332 $119.42 $636,747.44
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 17

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,347

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
SaleCommon Stock 14,661 $119.46 $1,751,403.06
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 16

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,679

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 326 $105.43 $34,370.18
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 15

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 85 $106.47 $9,049.95
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 14

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,293 $90.56 $207,654.08
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 13

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 1,642 $85.01 $139,586.42
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 12

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,623 $83.58 $219,230.34
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 11

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 3,023 $83.20 $251,513.60
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 10

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 1,643 $80.50 $132,261.50
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 9

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,864 $77.67 $222,446.88
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 8

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,623 $74.78 $196,147.94
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 7

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 9,459 $72.27 $683,601.93
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 6

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,072 $71.93 $149,038.96
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 5

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,759

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 3,148 $68.62 $216,015.76
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 4

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,709 $61.76 $167,307.84
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 3

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,284 $64.25 $146,747.00
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 2

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:04 UTC
Mayes Patrick AEVP & Chief Scientific Officer
Exercise / conversionCommon Stock 2,918 $61.18 $178,523.24
Disclosure

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 1

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 23, 2026 Filed Jul 27, 2026 22:23 UTC
Morrissey Michael JamesEVP, Head of Tech. Operations
GrantPerformance Shares · Derivative 8,999 $0.00 $0.00
Disclosure

SEC source: 0001780915-26-000010 · wk-form4_1785191009.xml · derivative · entry 2

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,999

Underlying: Common Stock · 8,999 shares

Expires 2029-07-23

F2 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F2 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 23, 2026 Filed Jul 27, 2026 22:23 UTC
Morrissey Michael JamesEVP, Head of Tech. Operations
GrantEmployee Stock Option (right to buy) · Derivative 6,426 $0.00 Strike: $116.69 $0.00
Disclosure

SEC source: 0001780915-26-000010 · wk-form4_1785191009.xml · derivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,426

Underlying: Common Stock · 6,426 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 23, 2026 Filed Jul 27, 2026 22:23 UTC
Heeson LeeEVP, Head of Incyte Intl
GrantPerformance Shares · Derivative 13,498 $0.00 $0.00
Disclosure

SEC source: 0002039219-26-000008 · wk-form4_1785190979.xml · derivative · entry 2

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,498

Underlying: Common Stock · 13,498 shares

Expires 2029-07-23

F2 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F2 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 23, 2026 Filed Jul 27, 2026 22:23 UTC
Heeson LeeEVP, Head of Incyte Intl
GrantEmployee Stock Option (right to buy) · Derivative 15,423 $0.00 Strike: $116.69 $0.00
Disclosure

SEC source: 0002039219-26-000008 · wk-form4_1785190979.xml · derivative · entry 1

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,423

Underlying: Common Stock · 15,423 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Tray ThomasPrincipal Accounting Officer
GrantEmployee Stock Option (right to buy) · Derivative 4,079 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0001912317-26-000015 · wk-form4_1784578233.xml · derivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,079

Underlying: Common Stock · 4,079 shares

Expires 2036-07-15

F3 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Tray ThomasPrincipal Accounting Officer
GrantCommon Stock 2,834 $0.00 $0.00
Disclosure

SEC source: 0001912317-26-000015 · wk-form4_1784578233.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,699

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 13,070 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Stein Steven HCMO & Head of Late-Stage Dev.
GrantEmployee Stock Option (right to buy) · Derivative 42,298 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 4

Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,298

Underlying: Common Stock · 42,298 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Stein Steven HCMO & Head of Late-Stage Dev.
GrantPerformance Shares · Derivative 24,496 $0.00 $0.00
Disclosure

SEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 3

Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,496

Underlying: Common Stock · 24,496 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Stein Steven HCMO & Head of Late-Stage Dev.
GrantCommon Stock 9,798 $0.00 $0.00
Disclosure

SEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 2

Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,916

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Stein Steven HCMO & Head of Late-Stage Dev.
SaleCommon Stock 1,877 $114.73 $215,348.21
Disclosure

SEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,118

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Mayes Patrick AEVP & Chief Scientific Officer
GrantEmployee Stock Option (right to buy) · Derivative 25,538 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · derivative · entry 3

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,538

Underlying: Common Stock · 25,538 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Mayes Patrick AEVP & Chief Scientific Officer
GrantPerformance Shares · Derivative 14,790 $0.00 $0.00
Disclosure

SEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · derivative · entry 2

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,790

Underlying: Common Stock · 14,790 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:10 UTC
Mayes Patrick AEVP & Chief Scientific Officer
GrantCommon Stock 5,916 $0.00 $0.00
Disclosure

SEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · nonDerivative · entry 1

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,628

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 74,327 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
CAGNONI PABLO JPresident, Global Head of R&D
GrantEmployee Stock Option (right to buy) · Derivative 57,861 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 3

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,861

Underlying: Common Stock · 57,861 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
CAGNONI PABLO JPresident, Global Head of R&D
GrantPerformance Shares · Derivative 33,508 $0.00 $0.00
Disclosure

SEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 2

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,508

Underlying: Common Stock · 33,508 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
CAGNONI PABLO JPresident, Global Head of R&D
GrantCommon Stock 13,403 $0.00 $0.00
Disclosure

SEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,332

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
Issa Mohamed KhairieEVP, Head of U.S. Commercial
GrantEmployee Stock Option (right to buy) · Derivative 33,918 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 4

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,918

Underlying: Common Stock · 33,918 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
Issa Mohamed KhairieEVP, Head of U.S. Commercial
GrantPerformance Shares · Derivative 19,643 $0.00 $0.00
Disclosure

SEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 3

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,643

Underlying: Common Stock · 19,643 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
Issa Mohamed KhairieEVP, Head of U.S. Commercial
GrantCommon Stock 7,857 $0.00 $0.00
Disclosure

SEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 2

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,797

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:09 UTC
Issa Mohamed KhairieEVP, Head of U.S. Commercial
SaleCommon Stock 1,093 $115.01 $125,705.93
Disclosure

SEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 1

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,940

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Basi Ramitpal KEVP, Human Resources
GrantEmployee Stock Option (right to buy) · Derivative 21,548 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · derivative · entry 3

Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,548

Underlying: Common Stock · 21,548 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Basi Ramitpal KEVP, Human Resources
GrantPerformance Shares · Derivative 12,479 $0.00 $0.00
Disclosure

SEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · derivative · entry 2

Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,479

Underlying: Common Stock · 12,479 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Basi Ramitpal KEVP, Human Resources
GrantCommon Stock 4,991 $0.00 $0.00
Disclosure

SEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · nonDerivative · entry 1

Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,497

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 11,497 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Gardner David HEVP, Chief Strategy Officer
GrantEmployee Stock Option (right to buy) · Derivative 31,923 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · derivative · entry 3

Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,923

Underlying: Common Stock · 31,923 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Gardner David HEVP, Chief Strategy Officer
GrantPerformance Shares · Derivative 18,487 $0.00 $0.00
Disclosure

SEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · derivative · entry 2

Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,487

Underlying: Common Stock · 18,487 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Gardner David HEVP, Chief Strategy Officer
GrantCommon Stock 7,395 $0.00 $0.00
Disclosure

SEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · nonDerivative · entry 1

Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,824

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 16,824 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Hoffman Richard A.EVP & General Counsel
GrantEmployee Stock Option (right to buy) · Derivative 31,923 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · derivative · entry 3

Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,923

Underlying: Common Stock · 31,923 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Hoffman Richard A.EVP & General Counsel
GrantPerformance Shares · Derivative 18,487 $0.00 $0.00
Disclosure

SEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · derivative · entry 2

Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,487

Underlying: Common Stock · 18,487 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:08 UTC
Hoffman Richard A.EVP & General Counsel
GrantCommon Stock 7,395 $0.00 $0.00
Disclosure

SEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · nonDerivative · entry 1

Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,861

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 16,861 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:07 UTC
Meury WilliamDirector · Chief Executive Officer
GrantEmployee Stock Option (right to buy) · Derivative 77,148 $0.00 Strike: $116.65 $0.00
Disclosure

SEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · derivative · entry 3

Meury William · CIK 0001536778 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,148

Underlying: Common Stock · 77,148 shares

Expires 2036-07-15

F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:07 UTC
Meury WilliamDirector · Chief Executive Officer
GrantPerformance Shares · Derivative 80,421 $0.00 $0.00
Disclosure

SEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · derivative · entry 2

Meury William · CIK 0001536778 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,421

Underlying: Common Stock · 80,421 shares

Expires 2029-07-16

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Read SEC document
July 16, 2026 Filed Jul 20, 2026 20:07 UTC
Meury WilliamDirector · Chief Executive Officer
GrantCommon Stock 26,807 $0.00 $0.00
Disclosure

SEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · nonDerivative · entry 1

Meury William · CIK 0001536778 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,129

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 178,883 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.